Suppr超能文献

探讨中药方剂雄黄-青黛治疗早幼粒细胞白血病的作用机制。

Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia.

作者信息

Wang Lan, Zhou Guang-Biao, Liu Ping, Song Jun-Hong, Liang Yang, Yan Xiao-Jing, Xu Fang, Wang Bing-Shun, Mao Jian-Hua, Shen Zhi-Xiang, Chen Sai-Juan, Chen Zhu

机构信息

State Key Laboratory of Medical Genomics and Shanghai Institute of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Road II, Shanghai 200025, China.

出版信息

Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4826-31. doi: 10.1073/pnas.0712365105. Epub 2008 Mar 14.

Abstract

To enhance therapeutic efficacy and reduce adverse effects, practitioners of traditional Chinese medicine (TCM) prescribe a combination of plant species/minerals, called formulae, based on clinical experience. Nearly 100,000 formulae have been recorded, but the working mechanisms of most remain unknown. In trying to address the possible beneficial effects of formulae with current biomedical approaches, we use Realgar-Indigo naturalis formula (RIF), which has been proven to be very effective in treating human acute promyelocytic leukemia (APL) as a model. The main components of RIF are realgar, Indigo naturalis, and Salvia miltiorrhiza, with tetraarsenic tetrasulfide (A), indirubin (I), and tanshinone IIA (T) as major active ingredients, respectively. Here, we report that the ATI combination yields synergy in the treatment of a murine APL model in vivo and in the induction of APL cell differentiation in vitro. ATI causes intensified ubiquitination/degradation of promyelocytic leukemia (PML)-retinoic acid receptor alpha (RARalpha) oncoprotein, stronger reprogramming of myeloid differentiation regulators, and enhanced G(1)/G(0) arrest in APL cells through hitting multiple targets compared with the effects of mono- or biagents. Furthermore, ATI intensifies the expression of Aquaglyceroporin 9 and facilitates the transportation of A into APL cells, which in turn enhances A-mediated PML-RARalpha degradation and therapeutic efficacy. Our data also indicate A as the principal component of the formula, whereas T and I serve as adjuvant ingredients. We therefore suggest that dissecting the mode of action of clinically effective formulae at the molecular, cellular, and organism levels may be a good strategy in exploring the value of traditional medicine.

摘要

为提高治疗效果并减少不良反应,中医从业者根据临床经验开出植物物种/矿物质的组合,即方剂。已记录了近10万种方剂,但大多数的作用机制仍不清楚。为了用当前的生物医学方法探究方剂可能的有益效果,我们使用已被证明在治疗人类急性早幼粒细胞白血病(APL)方面非常有效的雄黄-青黛方(RIF)作为模型。RIF的主要成分是雄黄、青黛和丹参,其中四硫化四砷(A)、靛玉红(I)和丹参酮IIA(T)分别为主要活性成分。在此,我们报告ATI组合在体内治疗小鼠APL模型以及体外诱导APL细胞分化方面产生协同作用。与单一或二元药物的作用相比,ATI通过作用于多个靶点导致早幼粒细胞白血病(PML)-维甲酸受体α(RARα)癌蛋白的泛素化/降解增强、髓系分化调节因子的重编程更强以及APL细胞中G(1)/G(0)期阻滞增强。此外,ATI增强水甘油通道蛋白9的表达并促进A进入APL细胞,这反过来增强了A介导的PML-RARα降解和治疗效果。我们的数据还表明A是该方剂的主要成分,而T和I作为辅助成分。因此,我们建议在分子、细胞和生物体水平剖析临床有效方剂的作用模式可能是探索传统医学价值的一个好策略。

相似文献

7
Understanding the molecular pathogenesis of acute promyelocytic leukemia.了解急性早幼粒细胞白血病的分子发病机制。
Best Pract Res Clin Haematol. 2014 Mar;27(1):3-9. doi: 10.1016/j.beha.2014.04.006. Epub 2014 Apr 13.

引用本文的文献

5
[The cure for acute promyelocytic leukemia and China's contributions].[急性早幼粒细胞白血病的治疗及中国的贡献]
Zhonghua Xue Ye Xue Za Zhi. 2025 May 14;46(5):377-384. doi: 10.3760/cma.j.cn121090-20250307-00119.
6
Advanced Pharmaceutical Nanotechnologies Applied for Chinese Herbal Medicines.应用于中草药的先进药物纳米技术
Adv Sci (Weinh). 2025 Aug;12(31):e00167. doi: 10.1002/advs.202500167. Epub 2025 Jun 20.

本文引用的文献

1
'Back to the future' for Chinese herbal medicines.中药“回到未来”
Nat Rev Drug Discov. 2007 Jul;6(7):506-7. doi: 10.1038/nrd2350.
7
Timeline: Chemotherapy and the war on cancer.时间线:化疗与抗癌之战
Nat Rev Cancer. 2005 Jan;5(1):65-72. doi: 10.1038/nrc1529.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验